(P027) Salvage of ‘Low-Risk’ Oral Tongue Failures Initially Managed With Surgery Alone-Importance of Recurrent Stage

Publication
Article
OncologyOncology Vol 28 No 1S
Volume 28
Issue 1S

Adjuvant therapy is not recommended after resection of oral tongue cancer in the absence of risk factors for recurrence. Having reported a 73% locoregional control rate for patients managed with surgery alone for ‘low-risk’ oral tongue cancer, this series examines our experience treating locoregional failures.

Thomas Galloway, MD, Dennis Sopka, MD, Tianyu Li, MS, Ranee Mehra, MD, Jeffrey Liu, MD, Miriam Lango, MD, Barbara Burtness, MD, John A. Ridge, MD, PhD; Fox Chase Cancer Center

Introduction: Adjuvant therapy is not recommended after resection of oral tongue cancer in the absence of risk factors for recurrence. Having reported a 73% locoregional control rate for patients managed with surgery alone for ‘low-risk’ oral tongue cancer, this series examines our experience treating locoregional failures.

Methods: Between 1990 and 2010, 126 patients at our institution were treated with primary surgery (+/− neck dissection) for stage I–II oral tongue cancer. Resection of locoregional recurrence was undertaken if clinically and technically indicated, followed by risk-adapted adjuvant therapy. Median follow-up after completion of salvage therapy was 3.0 years (range: 0.0–17.9 yr), including two patients who died during salvage radiation. Potential prognostic variables were analyzed. Kaplan-Meier curves were constructed to analyze outcomes.

Results: A total of 28 patients developed locoregional recurrence; median time to locoregional failure was 1.1 years (range: 0.4–4.5 yr), and 75% of failures occurred in the first 2 years. Failures were more common at the primary site (n = 19, 68%) than the neck (n = 9, 32%).

The majority (n = 21, 75%) was initially treated with an operation; the remaining patients were treated with definitive (chemo)radiation (n = 4) or declined further therapy (n = 3). Adjuvant radiation was delivered to 11 (51%) patients (2 with concurrent systemic therapy).

Locoregional control at 3 years was 81%, disease-free survival (DFS) was 70%, and overall survival (OS) was 54%. The strongest determinants of worse DFS were increasing recurrent T-stage (P = .008), neck recurrence (P = .06), and extracapsular spread in recurrent neck nodes (P = .008). Early-stage recurrences (recurrent stage T1–2 N0) did well (DFS, 100% at 3 years). The prognosis of neck failures was poor (DFS, 45% at 3 years).

Conclusions: Recurrence of low-risk oral tongue cancer can be successfully salvaged in the majority of cases. Neck failures have a worse prognosis than local failures.

Articles in this issue

(P113) Age and Marital Status Are Associated With Choice of Mastectomy in Patients Eligible for Breast Conservation Therapy
(P112) Single-Institution Experience With Intrabeam IORT for Treatment of Early-Stage Breast Cancer
(P110) Breast Cancer Before Age 40: Current Patterns in Clinical Presentation and Local Management
(P111) Accelerated Partial-Breast Irradiation With Multicatheter High-Dose-Rate Brachytherapy: Feasibility and Results in a Private Practice Cohort
(P115) Breast Cancer Laterality Does Not Influence Overall Survival in a Large Modern Cohort: Implications for Radiation-Related Cardiac Mortality
(P117) Anatomical Variations and Radiation Technique for Breast Cancer
(P116) Bilateral Immediate DIEP Reconstruction and Postmastectomy Radiotherapy: Experience at a Tertiary Care Institution
(P118) Metadherin Overexpression Is Associated With Improved Locoregional Control After Mastectomy
(P119) Effect of Economic Environment on Use of Postlumpectomy Radiation Therapy for Stage I Breast Cancer
(P120) Immediate Versus Delayed Reconstruction After Mastectomy in the United States Medicare Breast Cancer Patient
(P121) Trend in Age and Racial Disparities in the Receipt of Postlumpectomy Radiation Therapy for Stage I Breast Cancer: 2004–2009
(P122) Streamlining Referring Physicians Orders With ‘Reflex Testing’ Significantly Decreases Time to Resolution for Abnormal Screening Mammograms
(P123) National Trends in the Local Management of Early-Stage Paget Disease of the Breast
(P124) Effect of Inhomogeneity on Cardiac and Lung Dose in Partial-Breast Irradiation Using HDR Brachytherapy
(P125) Breast Cancer Outcomes With Anthracycline-Based Chemotherapy for Residual Disease Burden After Full-Dose Neoadjuvant Chemotherapy and Surgery Followed by Radiation Treatment
Recent Videos
Educating community practices on CAR T referral and sequencing treatment strategies may help increase CAR T utilization.
Harmonizing protocols across the health care system may bolster the feasibility of giving bispecifics to those with lymphoma in a community setting.
Although accuracy remains a focus in whole-body MRI testing in patients with Li-Fraumeni syndrome, comfortable testing experiences may ease anxiety.
Subsequent testing among patients in a prospective study may affirm the ability of cfDNA sequencing to detect cancers in those with Li-Fraumeni syndrome.
cfDNA sequencing may allow for more accessible, frequent, and sensitive testing compared with standard surveillance in Li-Fraumeni syndrome.
STX-478 showed efficacy in patients with advanced solid tumors regardless of whether they had kinase domain or helical PI3K mutations.
STX-478 may avoid adverse effects associated with prior PI3K inhibitors that lack selectivity for the mutated protein vs the wild-type protein.
Phase 1 data may show the possibility of rationally designing agents that can preferentially target PI3K mutations in solid tumors.
Funding a clinical trial to further assess liquid biopsy in patients with Li-Fraumeni syndrome may help with detecting cancers early across the board.
Related Content